Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + bevacizumab + erlotinib
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a four-drug combination regimen consisting of paclitaxel, carboplatin, bevacizumab, and erlotinib. Paclitaxel is a microtubule inhibitor that disrupts cell division; carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking; bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis; and erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling pathways. This combination has been studied in phase II clinical trials for the treatment of carcinoma of unknown primary (CUP), particularly in patients with adenocarcinoma or poorly differentiated carcinoma who have not received prior therapy[1][4]. The regimen aims to combine cytotoxic chemotherapy with targeted therapies to improve response rates.
- Other names
- paclitaxel and carboplatin and bevacizumab and erlotinib
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on paclitaxel + carboplatin + bevacizumab + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + bevacizumab + erlotinib.